Agencies, 19 October: Pune based Serum Institute of India aro Bharat Biotech para regulatory approval powa bechide intranasal coronavirus vaccine laga late-stage clinical trials lobo nesana ase. Etu khobor toh Sunday te Health Minister Harsh Vardhan para janaideya hisaab te ase. India te nasal corona virus vaccine laga clinical trials toh ahibole olob moina te suru koribole bhabona/biswas kori ase.
India te COVID-19 kelaaf tinta vaccine candidates toh manu khan ke test lobole nemide ase hoilebe etiya nemide trial pithor te intranasal vaccine candidate nai.
Union Minister Harsha Vardhan koise, late-stage trial te generally thousands hisha lowa- 30,000 to 40,000 nesana melikena ase.
Hyderabad-based drugs and vaccine research and manufacturing company toh nasal vaccine candidate laga trials nemide Washington University and St. Louis University logode agreement te kushise.
Vardhan para be US-based biotech company Codagenix para Serum Institute of India logode tusara intranasal vaccine laga development opor te khobor janaishe.
Tai koise, “Codagenix toh CDX-005 bonabo nemide Serum Institute of India logode melishe. Etu toh SARS-CoV-2 nemide company laga intranasal, live-attenuated vaccine candidate ase. Preclinical animal studies te kamiyaab hoikena kothom hoise aro Codagenix toh UK te 2020 sal kothom howa bechae para Phase 1 first-in-human clinical trial suru koribole bhabona ase”.
World Health Organization (WHO) hisaab te, CDX-005 toh ekta single dose intranasal vaccine ase aro etu toh virus laga live attenuated version logode bonaishe. Etu toh etiya Phase 3 trials te ase aro sob toh injection para shaishe (administered).
Add Comment